title: Incident neuropathy in HIV-infected patients on HAART.
abstract: We determined the incidence of and risk factors for distal sensory polyneuropathy (DSP) in individuals on HAART. Sixty-one HIV-positive subjects on HAART for at least 6 months and neuropathy free were retrospectively selected. The study included subjects who had previously tolerated d-drugs without developing DSP. Neuropathy incidence over 4 years was calculated. Cox proportional hazards models were used to determine risk factors associated with incident DSP. Nineteen subjects developed DSP over a mean follow-up of 2.4 years. Subjects never treated with a d-drug developed DSP at a rate of 21 cases per 100 person-years (95% CI, 8.9-33.7). Subjects with a history of d-drug treatment but not on a d-drug at enrollment developed DSP at a rate of 17 cases per 100 person-years (95% CI, 2.1-31.8). Those on d-drug treatment developed DSP at a rate of 25 cases per 100 person-years (95% CI, 8.7-41.6). Multivariable analysis identified age [hazard ratio (HR) = 1.09; p < 0.01] and low CD4(+) nadir [hazard ratio (HR) = 0.79; p = 0.03] as significant risk factors. Current or prior history of treatment with d-drug was not a significant risk factor for incident DSP in subjects who had previously tolerated d-drug treatment without developing a toxic DSP. Age and low CD4(+) are risk factors for incident DSP. However, current or prior history of d-drug treatment is not a significant risk factor for incident DSP in subjects who had previously tolerated d-drug treatment without developing a toxic DSP.
authors.affiliation: Hawaii Center for AIDS, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA. beau_nakamoto@yahoo.com
authors.forename: Beau K
authors.initials: BK
authors.lastname: Nakamoto
authors.forename: Aaron
authors.initials: A
authors.lastname: McMurtray
authors.forename: James
authors.initials: J
authors.lastname: Davis
authors.forename: Victor
authors.initials: V
authors.lastname: Valcour
authors.forename: Michael R
authors.initials: MR
authors.lastname: Watters
authors.forename: Bruce
authors.initials: B
authors.lastname: Shiramizu
authors.forename: Dominic C
authors.initials: DC
authors.lastname: Chow
authors.forename: Kalpana
authors.initials: K
authors.lastname: Kallianpur
authors.forename: Cecilia M
authors.initials: CM
authors.lastname: Shikuma
mesh_terms: D016263:AIDS-Associated Nephropathy / Q000453:epidemiology*; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents